Investors remain skeptical over Novo Nordisk's long-term growth prospects despite raised full-year guidance amid intensifying competition. Novo Nordisk raised its full-year guidance after reporting better-than-expected quarterly results, now expecting adjusted sales and op
The biotech firm priced 3.125 million shares to fund operations and growth, with underwriters holding a 30-day option for more. Twist Bioscience secured $300 million in gross proceeds by pricing 3.125 million common shares at $96.00 each in an upsized public offering. The
Global equities rally near 15% year-to-date gains as geopolitical and AI bubble concerns fade, compressing risk premia. Global equities surged as risk premia compressed, driven by reduced fears over the Iran conflict and a fading AI bubble rather than upgraded growth expec
Biotech firm Attovia Therapeutics secures $289M in its expanded IPO, pricing 17M shares at $17 each. Attovia Therapeutics priced its upsized initial public offering at $17 per share, raising approximately $289M in gross proceeds. The company sold 17M shares in the offering
The satellite communications firm reported earnings above expectations, matching year-ago results despite market challenges. ViaSat posted first-quarter earnings of $0.17 per share, exceeding the Zacks Consensus Estimate of $0.10 per share. The result matched the company’s
The micromobility firm forecasts $265M-$285M adjusted EBITDA for 2026 following a record Q2 2026 performance. Lime reported Q2 2026 revenue of $304 million, a 24% year-over-year increase, and adjusted EBITDA of $84 million, reflecting a 28% margin. The company also highlig
Ahold Delhaize reports Q2 Non-GAAP EPS of €0.63 Ahold Delhaize has released its Q2 earnings, with Non-GAAP EPS of €0.63. The company's revenue for the quarter was €23.2B, representing a 0.5% year-over-year increase. Comparable sales excluding gasoline increased 0
Higher commodity prices drive Glencore’s first-half earnings and revenue growth, with EBITDA up 72% year-over-year. Glencore reported first-half non-GAAP earnings per share of $0.31, as revenue surged 48.6% year-over-year to $174.43 billion. The company attributed the gain
Lucid Group aims to boost cash flow by $1.4 billion in 2026 while forecasting reduced production in the second half of this year. Lucid Group outlined a $1.4 billion cash flow improvement target for 2026 during its Q2 2026 earnings call. The electric vehicle maker expects
Syndax Pharmaceuticals reports combined Q2 sales of $115 million for Revuforj and Niktimvo, annualizing above $200 million each. Syndax Pharmaceuticals posted combined second-quarter sales of $115 million for its drugs Revuforj and Niktimvo. CEO Michael Metzger noted both
ادخل بحساب جوجل لمشاركة رأيك والتفاعل مع الأخبار — بلا كلمة مرور.
إيميلك يبقى موثّقاً وخصوصيتك محفوظة.